Opportunistic infection at the start of antiretroviral therapy and baseline CD4 + count less than 50 cells/mm  are associated with poor immunological recovery

dc.contributor.author	Tilak, Amod
dc.contributor.author	Shenoy, Smita
dc.contributor.author	Varma, Muralidhar
dc.contributor.author	Kamath, Asha
dc.contributor.author	Tripathy, Amruta
dc.contributor.author	Sori, Ravi K.
dc.contributor.author	Saravu, Kavitha
dc.date.accessioned	2019-11-04T08:37:22Z
dc.date.available	2019-11-04T08:37:22Z
dc.date.issued	2019
dc.identifier.citation	Journal of Basic and Clinical Physiology and Pharmacology. 2019; 30 (2): 163–171.	en_US
dc.identifier.issn	‎0792-6855
dc.identifier.uri	http://localhost:8080/xmlui/handle/123456789/1406
dc.language.iso	en	en_US
dc.publisher	Walter de Gruyter GmbH	en_US
dc.subject	Adherence	en_US
dc.subject	AIDS-related opportunistic infections	en_US
dc.subject	Anti-HIV agents-therapeutic use	en_US
dc.subject	CD4 lymphocite count	en_US
dc.subject	HIV infections-drug therapy	en_US
dc.title	Opportunistic infection at the start of antiretroviral therapy and baseline CD4 + count less than 50 cells/mm are associated with poor immunological recovery	en_US
dc.type	Article	en_US